S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:JUNO

Juno Therapeutics (JUNO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$86.96
▼
$86.96
50-Day Range
$86.96
▼
$86.96
52-Week Range
$19.62
▼
$87.01
Volume
2 shs
Average Volume
5.48 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media

JUNO stock logo

About Juno Therapeutics (NASDAQ:JUNO) Stock

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JUNO Stock News Headlines

May 18, 2023 | bizjournals.com
Cancer-fighting biotech startup Indapta lands $30M with assist from FDA
May 13, 2023 | marketwatch.com
2030, Multiple Myeloma Therapeutics Market: Trend & Outlook
June 10, 2023 | Vector Vest (Ad)
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
May 10, 2023 | finanznachrichten.de
Chinook Therapeutics, Inc.: Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
May 10, 2023 | marketwatch.com
2023-2031 "CAR T-Cell Therapy Market" Development: Key Players Analysis and Innovative Growth Opportunities
May 5, 2023 | marketwatch.com
2023-2030 Multiple Myeloma Therapeutics Market Size (Growth and Outlook) includes Sales Channel and Regional Analysis | with [101 Pages]
May 5, 2023 | marketwatch.com
CAR T-Cell Therapy Market Share and Forecast till 2030
May 3, 2023 | marketwatch.com
Global Indolent Lymphoma Treatment Market by Size, Trend & New Technology till 2023-2030
June 10, 2023 | Behind the Markets (Ad)
⚡ 2,467% Return on Israeli Laser Company?
This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.
April 29, 2023 | businessinsider.com
Juno review: Digital high-yield checking account with cash back rewards
April 29, 2023 | marketwatch.com
Multiple Myeloma Therapeutics Market Top Key Players by 2030
April 28, 2023 | marketwatch.com
CAR T-Cell Therapy Market Research Analysis 2023-2031
April 24, 2023 | marketwatch.com
Neuroblastoma Treatment Market Insights and Segmentation Until 2031
April 19, 2023 | marketwatch.com
CAR T-Cell Therapy Market 2023 Global Report Insights 2029
April 17, 2023 | bizjournals.com
Former Eliem CEO Bob Azelby joins board of Chinook Therapeutics
April 12, 2023 | finanznachrichten.de
Century Therapeutics, Inc.: Century Therapeutics Announces Leadership Changes
April 10, 2023 | finance.yahoo.com
Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel
April 3, 2023 | finance.yahoo.com
AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business Officer
March 30, 2023 | marketwatch.com
CAR-T Therapy Market Analysis by Global Report Research, 2029
March 27, 2023 | marketwatch.com
Multiple Myeloma Therapeutics Market | Newsest Research
March 26, 2023 | marketwatch.com
Global Multiple Myeloma Therapeutics Market In-Depth Analysis, Business Forecast, and Dynamics 2023 – 2030 By VMReports
March 17, 2023 | marketwatch.com
2023 to 2028 CAR T-Cell Therapy Market Forecasting Future Growth Outlook
March 14, 2023 | marketwatch.com
2029 Forecast CAR-T Therapy Market 2023 by Growth Rate, Sparked Innovation with Top Players
March 11, 2023 | marketwatch.com
Immune Repertoire Sequencing Market 2023-2028 New Review by Competitor Analysis and Recent Development
March 6, 2023 | marketwatch.com
CAR-T Therapy Market is Growing Globally Forecast 2023-2028
March 2, 2023 | marketwatch.com
2023-2029 Acute Lymphocytic Leukemia Therapeutics Market Size and Risks Factors Analysis | Survey Report by Absolute Reports
March 1, 2023 | marketwatch.com
Global Hairy Cell Leukemia Therapeutics Market Upcoming Trends, Opportunities by Types and Application to 2030 By VMReports
See More Headlines


JUNO Company Calendar

Last Earnings
11/01/2017
Today
6/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:JUNO
CUSIP
N/A
CIK
1594864
Web
www.junotherapeutics.com
Phone
+1-206-5821600
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A

Key Executives

  • Howard H. Pien (Age 59)
    Independent Chairman of the Board
  • Hans Edgar Bishop (Age 53)
    President, Chief Executive Officer, Director
  • Sunil Agarwal M.D. (Age 47)
    President of Research & Development
  • Steven D. Harr M.D. (Age 46)
    Chief Financial Officer, Head of Corporate Development
  • Hyam I. Levitsky M.D (Age 54)
    Executive vice president - Research, chief scientific officer
  • Robert W. Azelby (Age 49)
    Executive Vice President, Chief Commercial Officer
  • Ann Lee Ph.D.
    Executive Vice President - Technical Operations
  • Patrick Y. Yang (Age 69)
    Executive Vice President
  • Cynthia Elkins
    Chief Information Officer
  • Bernard J. Cassidy (Age 62)
    General Counsel, Secretary













JUNO Stock - Frequently Asked Questions

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. The firm's revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.57) earnings per share.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

What is Juno Therapeutics' stock price today?

One share of JUNO stock can currently be purchased for approximately $86.96.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The official website for the company is www.junotherapeutics.com. The biopharmaceutical company can be reached via phone at +1-206-5821600.

This page (NASDAQ:JUNO) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -